Lead-Quality

Lead-Quality is a Japanese biotechnology company spun out from Kanazawa University, specializing in the discovery and development of therapeutic monoclonal antibodies. The company utilizes a proprietary platform to generate high-quality lead antibodies against challenging targets, with a primary focus on membrane-bound proteases such as MT1-MMP (MMP14). Their research aims to address unmet medical needs in oncology and fibrotic diseases by developing highly specific inhibitors that modulate the tumor microenvironment. Lead-Quality provides both internal pipeline development and collaborative drug discovery services to pharmaceutical partners.